Literature DB >> 31910030

Trafficking of nonesterified fatty acids in insulin resistance and relationship to dysglycemia.

Rachel E Walker1, Jennifer L Ford1, Raymond C Boston2,3, Olga V Savinova4,5, William S Harris6, Michael H Green1, Gregory C Shearer1,4,6.   

Abstract

In adipose, insulin functions to suppress intracellular lipolysis and secretion of nonesterified fatty acid (NEFA) into plasma. We applied glucose and NEFA minimal models (MM) following a frequently sampled intravenous glucose tolerance test (FSIVGTT) to assess glucose-specific and NEFA-specific insulin resistance. We used total NEFA and individual fatty acids in the NEFA MM, comparing the model parameters in metabolic syndrome (MetSyn) subjects (n = 52) with optimally healthy controls (OptHC; n = 14). Results are reported as mean difference (95% confidence interval). Using the glucose MM, MetSyn subjects had lower [-73% (-82, -57)] sensitivity to insulin (Si) and higher [138% (44, 293)] acute insulin response to glucose (AIRg). Using the NEFA MM, MetSyn subjects had lower [-24% (-35, -13)] percent suppression, higher [32% (15, 52)] threshold glucose (gs), and a higher [81% (12, 192)] affinity constant altering NEFA secretion (ϕ). Comparing fatty acids, percent suppression was lower in myristic acid (MA) than in all other fatty acids, and the stearic acid (SA) response was so unique that it did not fit the NEFA MM. MA and SA percent of total were increased at 50 min after glucose injection, whereas oleic acid (OA) and palmitic acid (PA) were decreased (P < 0.05). We conclude that the NEFA MM, as well as the response of individual NEFA fatty acids after a FSIVGTT, differ between OptHC and MetSyn subjects and that the NEFA MM parameters differ between individual fatty acids.

Entities:  

Keywords:  adipose; compartmental modeling; fatty acids; insulin resistance

Mesh:

Substances:

Year:  2020        PMID: 31910030      PMCID: PMC7099405          DOI: 10.1152/ajpendo.00331.2019

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  42 in total

1.  Rapid separation of lipid classes in high yield and purity using bonded phase columns.

Authors:  M A Kaluzny; L A Duncan; M V Merritt; D E Epps
Journal:  J Lipid Res       Date:  1985-01       Impact factor: 5.922

2.  Multiexponential, multicompartmental, and noncompartmental modeling. II. Data analysis and statistical considerations.

Authors:  E M Landaw; J J DiStefano
Journal:  Am J Physiol       Date:  1984-05

3.  Spillover of dietary fatty acids and use of serum nonesterified fatty acids for the synthesis of VLDL-triacylglycerol under two different feeding regimens.

Authors:  Brian R Barrows; Maureen T Timlin; Elizabeth J Parks
Journal:  Diabetes       Date:  2005-09       Impact factor: 9.461

4.  Effect of liraglutide on estimates of lipolysis and lipid oxidation in obese patients with stable coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial.

Authors:  Christian Anholm; Preman Kumarathurai; Amirsalar Samkani; Lene R Pedersen; Raymond C Boston; Olav W Nielsen; Ole P Kristiansen; Mogens Fenger; Sten Madsbad; Ahmad Sajadieh; Steen B Haugaard
Journal:  Diabetes Obes Metab       Date:  2019-05-29       Impact factor: 6.577

5.  A novel minimal model to describe NEFA kinetics following an intravenous glucose challenge.

Authors:  Ray C Boston; Peter J Moate
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2008-01-30       Impact factor: 3.619

6.  MINMOD Millennium: a computer program to calculate glucose effectiveness and insulin sensitivity from the frequently sampled intravenous glucose tolerance test.

Authors:  Ray C Boston; Darko Stefanovski; Peter J Moate; Anne E Sumner; Richard M Watanabe; Richard N Bergman
Journal:  Diabetes Technol Ther       Date:  2003       Impact factor: 6.118

7.  What does the measurement of whole-body fatty acid rate of appearance in plasma by using a fatty acid tracer really mean?

Authors:  Bettina Mittendorfer; Olivia Liem; Bruce W Patterson; John M Miles; Samuel Klein
Journal:  Diabetes       Date:  2003-07       Impact factor: 9.461

8.  Effects of prescription niacin and omega-3 fatty acids on lipids and vascular function in metabolic syndrome: a randomized controlled trial.

Authors:  Gregory C Shearer; James V Pottala; Susan N Hansen; Verdayne Brandenburg; William S Harris
Journal:  J Lipid Res       Date:  2012-08-14       Impact factor: 5.922

Review 9.  Fatty acids, obesity, and insulin resistance: time for a reevaluation.

Authors:  Fredrik Karpe; Julian R Dickmann; Keith N Frayn
Journal:  Diabetes       Date:  2011-10       Impact factor: 9.461

10.  Postprandial enrichment of triacylglycerol-rich lipoproteins with omega-3 fatty acids: lack of an interaction with apolipoprotein E genotype?

Authors:  Valérie Conway; Marie-Julie Allard; Anne-Marie Minihane; Kim G Jackson; Julie A Lovegrove; Mélanie Plourde
Journal:  Lipids Health Dis       Date:  2014-09-16       Impact factor: 3.876

View more
  2 in total

Review 1.  Signaling through Free Fatty Acid Receptor 4 Attenuates Cardiometabolic Disease.

Authors:  Timothy D O'Connell; Katherine A Murphy; Naixin Zhang; Sara J Puccini; Chastity L Healy; Brian A Harsch; Michael J Zhang; Gregory C Shearer
Journal:  Physiology (Bethesda)       Date:  2022-08-09

2.  Associations of Serum Nonesterified Fatty Acids With Coronary Heart Disease Mortality and Nonfatal Myocardial Infarction: The CHS (Cardiovascular Health Study) Cohort.

Authors:  Neil K Huang; Petra Bůžková; Nirupa R Matthan; Luc Djoussé; Calvin H Hirsch; Jorge R Kizer; W T Longstreth; Kenneth J Mukamal; Alice H Lichtenstein
Journal:  J Am Heart Assoc       Date:  2021-03-08       Impact factor: 5.501

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.